Elan expects to pay $203.5 million to settle US law suit

Monday 26 July 2010

Elan Corporation Plc expects to pay $203.5 million as part of a settlement with the US relating to its sales and promotions of the epilepsy drug, Zonegran (zonisamide), a charge that largely accounted for the company’s second quarter loss of $213.1 million.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Ireland